Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease
- PMID: 27475656
- DOI: 10.1016/j.semnephrol.2016.05.002
Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease
Abstract
Dysregulated iron homeostasis plays a central role in the development of anemia of chronic kidney disease (CKD) and is a major contributor toward resistance to treatment with erythropoiesis-stimulating agents. Understanding the underlying pathophysiology requires an in-depth understanding of normal iron physiology and regulation. Recent discoveries in the field of iron biology have greatly improved our understanding of the hormonal regulation of iron trafficking in human beings and how its alterations lead to the development of anemia of CKD. In addition, emerging evidence has suggested that iron homeostasis interacts with bone and mineral metabolism on multiple levels, opening up new avenues of investigation into the genesis of disordered iron metabolism in CKD. Building on recent advances in our understanding of normal iron physiology and abnormalities in iron homeostasis in CKD, this review characterizes how anemia related to disordered iron metabolism develops in the setting of CKD. In addition, this review explores our emerging recognition of the connections between iron homeostasis and mineral metabolism and their implications for the management of altered iron status and anemia of CKD.
Keywords: Hepcidin; anemia of chronic kidney disease; chronic kidney disease; fibroblast growth factor 23; iron metabolism; vitamin D.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Iron Balance and the Role of Hepcidin in Chronic Kidney Disease.Semin Nephrol. 2016 Mar;36(2):87-93. doi: 10.1016/j.semnephrol.2016.02.001. Semin Nephrol. 2016. PMID: 27236128 Free PMC article. Review.
-
Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.Hematology. 2015 Oct;20(9):543-52. doi: 10.1179/1607845415Y.0000000004. Epub 2015 Mar 8. Hematology. 2015. PMID: 25745821
-
The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.Int J Mol Sci. 2019 Aug 27;20(17):4195. doi: 10.3390/ijms20174195. Int J Mol Sci. 2019. PMID: 31461904 Free PMC article. Review.
-
Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.Br J Clin Pharmacol. 2019 May;85(5):935-948. doi: 10.1111/bcp.13877. Epub 2019 Mar 4. Br J Clin Pharmacol. 2019. PMID: 30677788 Free PMC article. Clinical Trial.
-
Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond.Curr Med Chem. 2017;24(14):1417-1452. doi: 10.2174/0929867324666170316120538. Curr Med Chem. 2017. PMID: 28302014 Review.
Cited by
-
Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia.Front Nephrol. 2024 Oct 22;4:1459425. doi: 10.3389/fneph.2024.1459425. eCollection 2024. Front Nephrol. 2024. PMID: 39502472 Free PMC article. Review.
-
MOF-Based Platform for Kidney Diseases: Advances, Challenges, and Prospects.Pharmaceutics. 2024 Jun 11;16(6):793. doi: 10.3390/pharmaceutics16060793. Pharmaceutics. 2024. PMID: 38931914 Free PMC article. Review.
-
Sleep disorders in chronic kidney disease.Nat Rev Nephrol. 2024 Oct;20(10):690-700. doi: 10.1038/s41581-024-00848-8. Epub 2024 May 24. Nat Rev Nephrol. 2024. PMID: 38789686 Review.
-
Iron Metabolism and Inflammatory Mediators in Patients with Renal Dysfunction.Int J Mol Sci. 2024 Mar 27;25(7):3745. doi: 10.3390/ijms25073745. Int J Mol Sci. 2024. PMID: 38612557 Free PMC article. Review.
-
Ferroptosis: A New Mechanism in Diabetic Cardiomyopathy.Int J Med Sci. 2024 Jan 21;21(4):612-622. doi: 10.7150/ijms.88476. eCollection 2024. Int J Med Sci. 2024. PMID: 38464828 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
